

Christopher G Wood

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8832839/publications.pdf>

Version: 2024-02-01

230
papers

13,097
citations

²³⁸⁷⁹
60
h-index

³²¹⁸¹
105
g-index

243
all docs

243
docs citations

243
times ranked

11082
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive capacity of a miRNA panel in identifying teratoma in postchemotherapy consolidation surgeries. <i>BJU Compass</i> , 2023, 4, 81-87.	0.7	1
2	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. <i>BJU International</i> , 2022, 129, 610-620.	1.3	22
3	Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: <i>post hoc</i> analysis from Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG–ACRIN) E2805. <i>BJU International</i> , 2022, 129, 718-722.	1.3	1
4	Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1239-1246.	1.8	9
5	Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. <i>Cancers</i> , 2022, 14, 1127.	1.7	8
6	A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. <i>Laboratory Investigation</i> , 2022, 102, 554-559.	1.7	9
7	Prognostic significance of circulating insulin growth-like factor 1 and insulin growth-like factor binding protein 3 in renal cell carcinoma patients.. <i>American Journal of Cancer Research</i> , 2022, 12, 852-860.	1.4	0
8	Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. <i>European Urology Focus</i> , 2021, 7, 397-403.	1.6	12
9	Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2849.	1.8	5
10	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. <i>Cancers</i> , 2021, 13, 2170.	1.7	15
11	Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. <i>American Journal of Roentgenology</i> , 2021, 217, 1-7.	1.0	1
12	Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. <i>Translational Andrology and Urology</i> , 2021, 10, 2233-2245.	0.6	6
13	Long-term renal functional outcomes following ureteroureterostomy performed during multiorgan resection for nonurothelial cancers. <i>BJU Compass</i> , 2021, 2, 348-354.	0.7	2
14	Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e17-790.e23.	0.8	3
15	Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. <i>Cancers</i> , 2021, 13, 4006.	1.7	18
16	Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e401-e408.	0.9	14
17	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 837.e9-837.e17.	0.8	3
18	Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100349.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 6375.	5.8	22
20	The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Indian Journal of Urology</i> , 2021, 37, 13-19.	0.2	1
21	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. <i>Cancers</i> , 2021, 13, 6022.	1.7	14
22	Lymphangiobolization for iatrogenic chylous ascites after retroperitoneal urological surgery. <i>BJU International</i> , 2021, , .	1.3	0
23	The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. <i>European Urology Focus</i> , 2020, 6, 104-111.	1.6	18
24	Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. <i>European Urology Oncology</i> , 2020, 3, 687-694.	2.6	14
25	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 496-505.	0.8	6
26	Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Annals of Translational Medicine</i> , 2020, 8, 1037-1037.	0.7	5
27	Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease. <i>Cancer Journal (Sudbury,)</i> Tj ETQq1 1 0,784314 rgBT /Ove	1.0	1
28	Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. <i>Cancer</i> , 2020, 126, 4878-4885.	2.0	5
29	Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. <i>Cancers</i> , 2020, 12, 3755.	1.7	23
30	Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 329-343.	0.8	10
31	Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. <i>Cancer</i> , 2020, 126, 3950-3960.	2.0	34
32	Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. <i>BJU International</i> , 2020, 126, 745-753.	1.3	20
33	EDITORIAL COMMENT. <i>Urology</i> , 2020, 136, 175.	0.5	0
34	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. <i>Cancer Cell</i> , 2020, 37, 720-734.e13.	7.7	74
35	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	2.3	11
36	Conditional survival of patients with small renal masses undergoing active surveillance. <i>BJU International</i> , 2019, 123, 447-455.	1.3	14

#	ARTICLE	IF	CITATIONS
37	Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. <i>Modern Pathology</i> , 2019, 32, 1698-1707.	2.9	35
38	Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1937-1946.	1.9	19
39	Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. <i>Angewandte Chemie</i> , 2019, 131, 4223-4227.	1.6	0
40	Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 4179-4183.	7.2	8
41	Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. <i>Journal of Clinical Oncology</i> , 2019, 37, 2062-2071.	0.8	80
42	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	1.2	9
43	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 141-149.	2.6	73
44	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
45	Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. <i>World Journal of Urology</i> , 2018, 36, 1093-1101.	1.2	36
46	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. <i>Urology</i> , 2018, 115, 119-124.	0.5	19
47	Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. <i>Carcinogenesis</i> , 2018, 39, 752-757.	1.3	18
48	Adjuvant therapy for advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 663-671.	1.1	17
49	Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. <i>Urology</i> , 2018, 116, 114-119.	0.5	19
50	Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. <i>Palliative and Supportive Care</i> , 2018, 16, 146-154.	0.6	5
51	Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. <i>Annals of Surgery</i> , 2018, 268, 172-178.	2.1	75
52	Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. <i>Journal of Urology</i> , 2018, 199, 393-400.	0.2	70
53	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology's "Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2018, 121, 252-259.	1.3	61
54	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 52-52.	0.2	0

#	ARTICLE	IF	CITATIONS
55	BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. <i>Neoplasia</i> , 2018, 20, 32-43.	2.3	13
56	Radical Nephrectomy is the Treatment of Choice for Complex, Localized Renal Tumors. <i>Kidney Cancer</i> , 2018, 2, 5-9.	0.2	0
57	Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. <i>Cancer</i> , 2018, 124, 4023-4031.	2.0	30
58	Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. <i>American Journal of Pathology</i> , 2018, 188, 2487-2496.	1.9	34
59	Salvage topical therapy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018, 36, 2027-2034.	1.2	11
60	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e1-343.e8.	0.8	4
61	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2017, 35, 251-259.	1.2	33
62	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2017, 35, 113-120.	1.2	22
63	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 121-130.	1.2	37
64	Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. <i>Psycho-Oncology</i> , 2017, 26, 1361-1368.	1.0	22
65	Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 363-370.	0.9	17
66	Surgical Treatment for Renal Cell Carcinoma. , 2017, , 221-235.		0
67	Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. <i>Journal of Urology</i> , 2017, 198, 281-288.	0.2	47
68	Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. <i>Journal of Urology</i> , 2017, 198, 810-816.	0.2	26
69	Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. <i>Journal of Urology</i> , 2017, 198, 530-537.	0.2	55
70	Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-Related Genes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1436-1442.	1.1	2
71	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724.	5.8	106
72	Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. <i>Cancer</i> , 2017, 123, 3617-3627.	2.0	25

#	ARTICLE	IF	CITATIONS
73	Feasibility of Contrast-Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 1547-1553.	0.8	3
74	Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. <i>Nature Communications</i> , 2017, 8, 783.	5.8	157
75	Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. <i>Cancer</i> , 2017, 123, 4823-4831.	2.0	79
76	Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. <i>Journal of Endourology</i> , 2017, 31, 946-953.	1.1	33
77	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. <i>Clinical Cancer Research</i> , 2017, 23, 6686-6696.	3.2	66
78	The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. <i>Urology</i> , 2017, 108, 114-121.	0.5	11
79	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 747-754.	0.9	39
80	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2017, 198, 1269-1277.	0.2	5
81	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 198, 1253-1262.	0.2	58
82	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 197, 580-589.	0.2	35
83	Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial. <i>Journal of Urology</i> , 2017, 197, 559-565.	0.2	10
84	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2017, 35, 1073-1080.	1.2	12
85	Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2017, 1, 115-121.	0.2	7
86	The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. <i>Journal of Urology</i> , 2016, 196, 678-684.	0.2	24
87	The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2016, 8, 130-141.	0.9	57
88	Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. <i>Cancer</i> , 2016, 122, 108-115.	2.0	24
89	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. <i>Cancer</i> , 2016, 122, 1836-1843.	2.0	39
90	Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. <i>BJU International</i> , 2016, 117, E87-94.	1.3	39

#	ARTICLE	IF	CITATIONS
91	Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. <i>BJU International</i> , 2016, 117, 775-782.	1.3	65
92	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. <i>Urology</i> , 2016, 94, 314.e1-314.e7.	0.5	16
93	DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2016, 22, 6236-6246.	3.2	47
94	Variability of interobserver agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (<sc>RCC</sc>): independent analysis from a phase II trial. <i>BJU International</i> , 2016, 117, 629-635.	1.3	18
95	Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. <i>Clinical Cancer Research</i> , 2016, 22, 2074-2082.	3.2	22
96	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. <i>European Urology</i> , 2016, 69, 866-874.	0.9	272
97	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. <i>European Urology</i> , 2016, 70, 348-357.	0.9	111
98	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46	0.3	529
99	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. <i>World Journal of Urology</i> , 2016, 34, 1155-1161.	1.2	4
100	Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 237.e19-237.e26.	0.8	13
101	Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. <i>European Urology</i> , 2016, 69, 352-360.	0.9	14
102	Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 427.e17-427.e23.	0.8	35
103	Surgical considerations for patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 528-537.	0.8	23
104	Reporting Geographic and Temporal Trends in Renal Cell Carcinoma: Why Is This Important?. <i>European Urology</i> , 2015, 67, 531-532.	0.9	6
105	Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. <i>Psycho-Oncology</i> , 2015, 24, 1477-1484.	1.0	23
106	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1017-1029.	1.6	159
107	Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. <i>Modern Pathology</i> , 2015, 28, 1225-1235.	2.9	23
108	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. <i>European Urology</i> , 2015, 68, 980-992.	0.9	206

#	ARTICLE	IF	CITATIONS
109	Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 166.e21-166.e29.	0.8	44
110	Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. <i>Journal of Urology</i> , 2015, 194, 316-322.	0.2	49
111	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 495.e15-495.e22.	0.8	15
112	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2015, 33, 1965-1972.	1.2	9
113	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2015, 193, 1486-1493.	0.2	38
114	Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. <i>Cancer Research</i> , 2015, 75, 4131-4142.	0.4	38
115	Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 388.e1-388.e9.	0.8	36
116	Mucinous tubular and spindle cell carcinoma (<sc>MTSCC</sc>) of the kidney: a detailed study of radiological, pathological and clinical outcomes. <i>BJU International</i> , 2015, 116, 85-92.	1.3	44
117	Cytoreductive Nephrectomy. , 2015, , 157-171.		0
118	Cytoreductive surgery in the era of targeted molecular therapy. <i>Translational Andrology and Urology</i> , 2015, 4, 301-9.	0.6	3
119	Treating the Two Extremes in Renal Cell Carcinoma: Management of Small Renal Masses and Cytoreductive Nephrectomy in Metastatic Disease. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e214-e221.	1.8	5
120	Positive vascular wall margins have minimal impact on cancer outcomes in patients with nonâ€metastatic renal cell carcinoma (<sc>RCC</sc>) with tumour thrombus. <i>BJU International</i> , 2014, 114, 667-673.	1.3	29
121	Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes. <i>Clinical Cancer Research</i> , 2014, 20, 4129-4140.	3.2	117
122	Surgical Management of Renal Cell Carcinoma. <i>Seminars in Interventional Radiology</i> , 2014, 31, 027-032.	0.3	46
123	Partial Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 36-42.	0.2	12
124	Perioperative Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Cava Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Experience. <i>European Urology</i> , 2014, 66, 584-592.	0.9	100
125	Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 561-568.	0.8	28
126	Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 874-880.	0.9	131

#	ARTICLE	IF	CITATIONS
127	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 66, 379-385.	0.9	27
128	Biomarkers of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 243-251.	0.8	40
129	Neuroendocrine Tumors of the Kidney: A Single Institution Experience. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 422-427.	0.9	21
130	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	0.5	18
131	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. <i>Cancer</i> , 2014, 120, 1794-1799.	2.0	154
132	Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. <i>World Journal of Urology</i> , 2014, 32, 631-642.	1.2	45
133	Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Cohort. <i>Journal of Urology</i> , 2014, 192, 1050-1056.	0.2	76
134	Re: Prognostic or Predictive Plasma Cytokines and Angiogenic Factors for Patients Treated with Pazopanib for Metastatic Renal-cell Cancer: A Retrospective Analysis of Phase 2 and Phase 3 Trials. <i>European Urology</i> , 2013, 63, 769.	0.9	1
135	Adjuvant and neoadjuvant therapy for renal cell carcinoma: A survey of the Society of Urologic Oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1316-1320.	0.8	17
136	Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 947-952.	0.9	67
137	Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus. <i>Journal of Urology</i> , 2013, 190, 452-457.	0.2	25
138	Refining the Use of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2013, 40, 429-435.	0.8	6
139	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. <i>European Urology</i> , 2013, 63, 1082-1090.	0.9	98
140	Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. <i>European Urology</i> , 2013, 63, 1122-1127.	0.9	88
141	Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 676-681.	0.8	4
142	Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2013, 81, 972-978.	0.5	55
143	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. <i>Journal of Urology</i> , 2013, 189, 1662-1669.	0.2	152
144	Locally Advanced Renal Cell Carcinoma. , 2013, , 197-218.		0

#	ARTICLE	IF	CITATIONS
145	Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 190, 386-388.	0.2	5
146	Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. <i>European Journal of Endocrinology</i> , 2013, 169, 891-899.	1.9	235
147	Autotaxin-1/Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 6461-6472.	3.2	41
148	Genomic Heterogeneity of Translocation Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 4673-4684.	3.2	77
149	Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 614-621.	0.7	10
150	Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. , 2013, , 155-177.		0
151	Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. <i>International Journal of Urology</i> , 2012, 19, 1060-1066.	0.5	64
152	Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2012, 39, 211-231.	0.8	24
153	Renal Tumors. , 2012, , 287-309.		0
154	Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. <i>European Urology</i> , 2012, 62, 100-114.	0.9	349
155	The Effects of Temporary Ischemia in Partial Nephrectomy on Renal Functional Outcomes: How Can Effects Best Be Estimated, and Can They Be Mitigated?. <i>European Urology</i> , 2012, 62, 136-138.	0.9	2
156	Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial. <i>European Urology</i> , 2012, 62, 182-183.	0.9	2
157	Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. <i>BJU International</i> , 2012, 110, 1742-1746.	1.3	55
158	Metabolic evaluation of sporadic papillary kidney cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 377-377.	0.8	0
159	The Role of Lymph Node Dissection in Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2011, 38, 419-428.	0.8	6
160	Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. <i>Journal of Urology</i> , 2011, 185, 439-444.	0.2	113
161	The Role of Surgery in Advanced Renal Cell Carcinoma: Cytoreductive Nephrectomy and Metastasectomy. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 753-764.	0.9	22
162	Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2011, 77, 861-866.	0.5	31

#	ARTICLE	IF	CITATIONS
163	Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 716-723.	0.8	73
164	Can a Durable Disease-Free Survival be Achieved With Surgical Resection in Patients With Pathological Node Positive Renal Cell Carcinoma?. <i>Journal of Urology</i> , 2011, 186, 1236-1241.	0.2	53
165	Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib. <i>European Urology</i> , 2011, 60, 1273-1279.	0.9	69
166	Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2011, 108, 1286-1291.	1.3	71
167	Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. <i>BJU International</i> , 2011, 108, E304-E309.	1.3	44
168	Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 10-15.	0.9	98
169	Development and Characterization of Clinically Relevant Tumor Models From Patients With Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 619-628.	0.9	57
170	The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus. <i>European Urology</i> , 2011, 59, 912-918.	0.9	167
171	The RENAL Nephrometry Nomogram: Statistically Significant, But Is It Clinically Relevant?. <i>European Urology</i> , 2011, 60, 249-251.	0.9	14
172	Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 964-971.	0.9	89
173	International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 673-683.	0.9	25
174	The role of lymph node dissection in renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2011, 16, 186-94.	1.0	6
175	Renal Cell Carcinoma: What the Surgeon and Treating Physician Need to Know. <i>American Journal of Roentgenology</i> , 2011, 196, 1255-1262.	1.0	13
176	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. <i>European Urology</i> , 2010, 57, 1072-1079.	0.9	155
177	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. <i>European Urology</i> , 2010, 57, 575-581.	0.9	154
178	Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. <i>European Urology</i> , 2010, 58, 819-828.	0.9	89
179	Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. <i>Cancer</i> , 2010, 116, 3378-3388.	2.0	183
180	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. <i>Cancer</i> , 2010, 116, 3127-3134.	2.0	208

#	ARTICLE	IF	CITATIONS
181	Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2010, 184, 453-458.	0.2	182
182	Percutaneous Biopsy of Primary Tumor in Metastatic Renal Cell Carcinoma to Predict High Risk Pathological Features: Comparison With Nephrectomy Assessment. <i>Journal of Urology</i> , 2010, 184, 1877-1881.	0.2	67
183	Papillary Renal Cell Carcinoma: Radiologic-Pathologic Correlation and Spectrum of Disease. <i>Radiographics</i> , 2009, 29, 741-754.	1.4	123
184	Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. <i>Nature Reviews Urology</i> , 2009, 6, 375-383.	1.9	44
185	Role of cytoreductive nephrectomy in renal cell carcinoma. <i>Future Oncology</i> , 2009, 5, 859-869.	1.1	11
186	Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4076-4081.	0.8	183
187	Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. <i>Cancer</i> , 2009, 115, 1224-1233.	2.0	943
188	Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic disease. <i>Cancer</i> , 2009, 115, 2355-2360.	2.0	62
189	Pre-surgical targeted molecular therapy in renal cell carcinoma. <i>BJU International</i> , 2009, 103, 150-153.	1.3	16
190	Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. <i>BJU International</i> , 2009, 104, 456-460.	1.3	53
191	Predictors of Oncological Outcome After Resection of Locally Recurrent Renal Cell Carcinoma. <i>Journal of Urology</i> , 2009, 181, 2044-2051.	0.2	94
192	Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. <i>Urology</i> , 2009, 73, 337-341.	0.5	32
193	PERCUTANEOUS PRIMARY TUMOR BIOPSY IS UNRELIABLE TO PREDICT HIGH RISK PATHOLOGIC FEATURES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2009, 181, 501-501.	0.2	3
194	Vitespen: a preclinical and clinical review. <i>Future Oncology</i> , 2009, 5, 763-774.	1.1	43
195	The role of lymphadenectomy in renal cell carcinoma. <i>Current Opinion in Urology</i> , 2009, 19, 465-472.	0.9	19
196	Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. <i>Current Oncology Reports</i> , 2008, 10, 253-258.	1.8	9
197	Local recurrence after primary therapy for clinically localized prostate cancer: Is radiation or surgery "Better" in the salvage setting?. <i>Journal of Surgical Oncology</i> , 2008, 97, 376-376.	0.8	0
198	Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments. <i>Cancer</i> , 2008, 112, 955-961.	2.0	6

#	ARTICLE	IF	CITATIONS
199	Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. <i>Cancer</i> , 2008, 112, 1480-1488.	2.0	95
200	Is patient performance status always an accurate surrogate for predicting tumor biology in patients with metastatic renal cancer?. <i>Cancer</i> , 2008, 113, 1282-1283.	2.0	2
201	Cytoreductive Nephrectomy in the Era of Targeted Molecular Agents: Is It Time to Consider Presurgical Systemic Therapy?. <i>European Urology</i> , 2008, 54, 489-492.	0.9	25
202	An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. <i>Lancet, The</i> , 2008, 372, 145-154.	6.3	312
203	A vaccine for renal cancer. <i>Lancet, The</i> , 2008, 372, 1460-1461.	6.3	8
204	Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma. <i>Journal of Urology</i> , 2008, 180, 94-98.	0.2	157
205	Type III Transforming Growth Factor- β (TGF- β) Receptor Mediates Apoptosis in Renal Cell Carcinoma Independent of the Canonical TGF- β Signaling Pathway. <i>Clinical Cancer Research</i> , 2008, 14, 5722-5730.	3.2	24
206	The Role of Lymph Node Dissection in Renal Cell Carcinoma: The Pendulum Swings Back. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 308-314.	1.0	32
207	Cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2008, 18, 474-480.	0.9	17
208	Adjuvant approaches to renal cell carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 19-21.	0.3	5
209	Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome. <i>Clinical Cancer Research</i> , 2007, 13, 697s-702s.	3.2	68
210	Cytoreductive Nephrectomy for T4NxM1 Renal Cell Carcinoma: The M.D. Anderson Cancer Center Experience. <i>Urology</i> , 2007, 69, 835-838.	0.5	23
211	Update on staging controversies for locally advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 909-914.	1.1	4
212	Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma With Nonclear Cell Histology. <i>Journal of Urology</i> , 2007, 178, 1896-1900.	0.2	62
213	Cytoreductive Nephrectomy in the Elderly Patient: The M. D. Anderson Cancer Center Experience. <i>Journal of Urology</i> , 2007, 177, 855-861.	0.2	61
214	Renal cell carcinoma clinically involving adjacent organs. <i>Cancer</i> , 2007, 109, 2025-2030.	2.0	68
215	Redefining pT3 renal cell carcinoma in the modern era. <i>Cancer</i> , 2007, 109, 2439-2444.	2.0	55
216	Renal Cell Carcinoma With Nodal Metastases in the Absence of Distant Metastatic Disease (Clinical) <i>Tj ETQq0 0 0 rgBT /Overlock 10 TF 5</i> 2006, 175, 864-869.	0.2	116

#	ARTICLE	IF	CITATIONS
217	Chylous Ascites After Post-Chemotherapy Retroperitoneal Lymph Node Dissection: Review of the M. D. Anderson Experience. <i>Journal of Urology</i> , 2006, 176, 1463-1467.	0.2	101
218	Laparoscopic cytoreductive nephrectomy: The M. D. Anderson Cancer Center experience. <i>Urology</i> , 2006, 68, 528-532.	0.5	51
219	Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?. <i>BJU International</i> , 2006, 98, 1176-1180.	1.3	116
220	Adjuvant Therapy for Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2006, 33, 576-582.	0.8	44
221	Treatment of patients with metastatic renal cell cancer. <i>Cancer</i> , 2006, 107, 2375-2383.	2.0	63
222	Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. <i>Journal of Surgical Oncology</i> , 2006, 94, 264-265.	0.8	9
223	Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 2763-2771.	0.8	652
224	Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 3316-3322.	0.8	353
225	A renal mass in the setting of a nonrenal malignancy. <i>Cancer</i> , 2004, 101, 2195-2201.	2.0	59
226	The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. <i>Urologic Clinics of North America</i> , 2003, 30, 581-588.	0.8	50
227	Spontaneous Regression of Pulmonary Metastases From Renal Cell Carcinoma After Radio Frequency Ablation of Primary Tumor: In Situ Tumor Vaccine?. <i>Journal of Urology</i> , 2003, 170, 178-179.	0.2	104
228	Discovery and Characterization of Endometrial Epithelial Messenger Ribonucleic Acids Using the Ovine Uterine Gland Knockout Model. <i>Endocrinology</i> , 1999, 140, 4070-4080.	1.4	103
229	Tumor-suppressive activity of CD66a in prostate cancer. <i>Cancer Gene Therapy</i> , 1999, 6, 313-321.	2.2	75
230	Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. <i>Oncogene</i> , 1997, 14, 1697-1704.	2.6	94